Objective: Endothelin-1 (ET-1) potentiates norepinephrine (NE)-induced contractile responses. An impairment of cardiac NE re-uptake by the neuronal NE transporter (NET) contributes to an increased NE net release in failing hearts. We hypothesized that both phenomena are caused by ET-1-mediated inhibition of NET.
Introduction
Endothelin-1 (ET-1) is a ubiquitous 21 amino-acid peptide discovered as a potent vasoconstrictor [1] . Among various functions on the cardiovascular, pulmonary, renal and neuroendocrine systems [2] , ET-1 has also the ability to potentiate norepinephrine (NE)-induced effects on vascular smooth muscle cells [3] [4] [5] [6] [7] [8] . In congestive heart failure (CHF), elevated ET-1 plasma levels have been shown to promote sympatho-adrenergic overstimulation of failing hearts [9] [10] [11] [12] , but the underlying mechanisms are not fully understood. Though potentiation of NE-induced effects by ET-1 might be explained by increased calcium sensitivity of the contractile apparatus (postsynaptic effect), there is also evidence for a presynaptic mechanism of ET-1 on NE release from the sympathetic nerve ending [13 -20] .
The number of NE molecules that bind to postsynaptic adrenoceptors is not only determined by the release of the amine from the peripheral nerve ending but also by its elimination. After its release into the synaptic cleft more than 90% of NE is removed by neuronal re-uptake (uptake 1 ) via the NE transporter (NET), whereas extraneuronal uptake (uptake 2 ) of the amine plays only a minor role in the heart [21] . Any impairment of NET-mediated NE re-uptake would markedly increase the ''effective'' NE concentration at postsynaptic adrenoceptors. An impairment of cardiac NE re-uptake by NET downregulation contributes to the increased cardiac net release of NE in CHF, which is associated with depletion of cardiac NE stores, downregulation of cardiac beta-adrenoceptors and profound alterations of post-receptor signal coupling [21 -26] . Clinical studies have shown that impaired cardiac NE re-uptake is associated with poor prognosis (reflected by worsening of CHF and increasing incidence of sudden death) [27] . In an experimental CHF model, we have recently reported that an impairment of NE re-uptake is mediated by posttranscriptional NET downregulation [26] . In cell culture, it has been shown that activation of protein kinase C (PKC) induces translocation of NET from the plasma membrane to the cytoplasm [28, 29] .
We hypothesized that activation of presynaptic receptors, which are associated with PKC activation, might be involved in NET downregulation. Here we demonstrate that ET-1 via activation of endothelin-A-receptors (ET A ) potentiates the NE-induced increase in cardiac contractility by inhibition of NET. Moreover, we report that ET A antagonism improves NET function in experimental CHF.
Materials and methods
The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and was approved by the authorities of the Regierungspräsidium Karlsruhe, Germany.
Isolated heart perfusion
Wistar rats were anesthetized with thiopental (100 mg/kg i.p.). The hearts were rapidly cut out, rinsed in ice-cold buffer and the aorta was cannulated for perfusion according to Langendorff (1895). Within one experiment, 8 -12 spontaneously beating hearts were perfused simultaneously at a constant coronary flow and a constant temperature of 37.5 -C. The perfusion medium was a modified KrebsHenseleit solution (composition in mmol/L: NaCl 125, NaHCO 3 16.9, Na 2 HPO 4 0.2, KCl 4.0, CaCl 2 1.85, MgCl 2 1.0, glucose 11, EDTA 0.027). The buffer was gassed with 95% O 2 and 5% CO 2 and the pH was adjusted to 7.4.
Cardiac [ 3 H]-NE uptake was determined as described previously [26] . Briefly, a bolus of [ 3 H]-NE (1 mL, 3 ACi, 100 pmol NE; Amersham-Buchler, Braunschweig, Germany) was injected into the perfusion system and proportionally distributed to the hearts and blank channels. Radioactivity was measured in the effluent. The amount of [ 3 H]-NE, which was extracted by the hearts (uptake), is expressed as the percentage of radioactivity measured in the blank channels.
Overflow of endogenous NE was evoked by electrical field stimulation as described previously [26] . Briefly, isolated perfused hearts were stimulated with bipolar platinum electrodes (1 min, 4 Hz, 5 V). Two or three subsequent electrical stimulations were applied with an interval of 10 min in the presence of atropine (1 Amol/L) to prevent vagal activation. To distinguish between exocytotic and net release of NE, experiments were performed in the absence and presence of the NET inhibitor desipramine (DMI). Drugs were added 10 min prior to stimulations as indicated. Endogenous NE in the coronary venous effluate were determined by HPLC and electrochemical detection.
Coronary perfusion pressure was measured via a Statham P23 b transducer (Gould, Cleveland, OH, USA) connected to a side arm of the perfusion system.
Isovolumically contracting hearts were prepared according to Hampton et al. [30] . Briefly, isolated hearts were perfused at a constant coronary flow. A left atrial incision was made to expose the mitral annulus, through which a water-filled latex balloon attached to a catheter system was passed into the left ventricle. The distal end of the catheter was connected via a larger catheter to another Statham transducer to record the left ventricular (LV) pressure (LVP). LV-dp/dt max and mean perfusion pressure (PP) were calculated to assess cardiac function and coronary vasoconstriction.
The following agents were used: ET-1, BQ123, BQ788, sarafotoxin S6c, S-nitrosocaptopril (Calbiochem, Schwalbach, Germany), methoxamine, nicotine, bradykinin, angiotensin II, atropine, DMI, NE and isoprenaline (Sigma, Munich, Germany).
Experimental heart failure
Transverse aortic constriction (TAC) was performed as described previously [26] . Briefly, Wistar rats (90 g) were anesthetized with ketamine and diazepam. After thoracotomy the ascending aorta was partially occluded using tantalum hemostatic clips with a defined internal diameter of 0.71 mm. Some animals were treated with darusentan (30 mg/kg/day in the drinking water; kindly provided from Knoll AG, Ludwigshafen, Germany). A control group was sham operated. After 28 days the rats were anesthetized with thiopental. Blood samples were taken from the femoral vein for determination of plasma proANP. Lungs were excised for measuring the lung wet weight. Hearts were excised, weighed and used for (i) isolated heart perfusion, (ii) determination of LV-ET-1 or (iii) plasma membrane preparations and subsequently [ 3 H]-mazindol binding.
Plasma proANP and tissue ET-1
Plasma proANP and tissue ET-1 were determined using ELISA according to the manufacturers instructions (Biomedica, Vienna, Austria).
[ 3 H]-mazindol binding
Plasma membranes of left ventricles were prepared as described before [26] . Radioligand binding assays were performed in a total volume of 250 AL containing 50 Ag of plasma membranes and increasing concentrations of [
3 H]-mazindol (specific activity 52, 5 Ci/mmol; NEN, Dreieich, Germany) as a specific ligand. Non-specific binding was determined by measuring the residual binding in the presence of DMI (100 Amol/L). The incubation was carried out at 30 -C and terminated by rapid vacuum filtration through a MultiScreenHTS-FB filter plate (Millipore, Schwalbach, Germany). All experiments were performed in triplicate. The remaining filter radioactivity was determined, and B max was calculated using GraphPad Prism version 4.00 software (GraphPad Software, San Diego, California, USA).
Animals
For all experiments male Wistar rats were used. 180 healthy animals (180 -250 g) were used for cardiac [ 3 H]-NE uptake (n = 116), electrical field stimulation (n = 42) or preparation of isovolumically contracting hearts (n = 22). 52 male Wistar rats (90 g) underwent sham (n = 18) and TAC surgery (n = 34). 13 of TAC-operated rats were treated with the ET A antagonist darusentan. Sham-and TAC-rats were used for determination of LV-ET-1 (n = 8), cardiac [ 3 H]-NE uptake (n = 25) and LV-[
3 H]-mazindol binding (n = 19).
Statistical methods
The results are expressed as means T SEM. Statistical analysis was performed with the GraphPad Prism version 4.00 software. Intra-individual differences were tested with the paired t test and ANOVA for repeated measurements. Differences between groups were tested with the MannWhitney test. A p-value of <0.05 was considered significant. 
Results

ET-1 inhibits NE re-uptake via ET
p<0.05 n.s. (Fig. 1B) , identifying ET A as the predominant endothelin receptor subtype in regulation of NE re-uptake. Likewise, sarafotoxin S6c (StxS6c), a specific ET B agonist, did not reduce cardiac [ 3 H]-NE-uptake after perfusion periods of 15, 30 (data not shown) and 45 min (Fig. 1B) . Perfusion of BQ123 or BQ788 alone did not affect cardiac [
3 H]-NE-uptake (data not shown).
One could argue that the ET-1-induced phenomenon is nonspecifically mediated by ET A -mediated severe vasoconstriction and subsequent ischemia. Therefore, cardiac [ 3 H]-NE-uptake experiments were performed in the presence of the vasodilatator S-nitrosocaptopril (S-NC). S-NC completely normalized ET-1-induced increase in perfusion pressure ( Fig. 2A) but did not prevent ET-1-induced inhibition of cardiac [ 3 H]-NE-uptake (Fig. 2B ). S-NC by itself did not affect cardiac [ 3 H]-NE-uptake (Fig. 2B) , also indicating that the coronary vascular tone does not affect [ 3 H]-NE-uptake.
Effects of ET-1 on stimulated overflow of endogenous NE
Given that ET-1 inhibits cardiac NE re-uptake, an enhanced NE overflow after stimulation of cardiac sympathetic nerves would be expected. In fact, after 10 min preperfusion with 10 nmol/L ET-1, but not with StxS6c, electrical field stimulation-evoked overflow of endogenous NE was enhanced as compared to preperfusion with tyrode (Fig. 3) . To rule out that the enhanced NE overflow was due to an increase in exocytotic NE release, the same experiment was performed in the presence of the NET inhibitor DMI. Under these conditions ET-1 did not lead to an enhanced NE overflow. In contrast, presence of DMI exerted the opposite effect: NE overflow was markedly inhibited by ET-1, suggesting an additional inhibitory effect of ET-1 on exocytotic NE release (Fig.  3) . In contrast to the inhibitory effect of ET-1 on cardiac [ 3 H]-NE-uptake, the latter effect was not blocked by BQ123 but significantly attenuated by BQ788 and mimicked by StxS6c, indicating that the inhibitory effect on NE overflow is mediated by ET B (Fig. 3). 3.3. ET-1 potentiates NE-induced increase in LV-dp/dt max via NET To further investigate the functional relevance of ET-1-induced reduction of cardiac NE re-uptake, the increase in LV-dp/dt max in response to NE and the beta-adrenergic agonist isoprenaline (Iso) were measured in the absence and the presence of ET-1. Since Iso is not taken up by NET [24] , its removal from the circulation occurs in a way that is similar to NE after NET blockade. ET-1 alone (100 pmol/L) increased LV-dp/dt max after 30 min preperfusion by 25% (2.5 T 0.1 vs 1.7 T 0.1 mmHg/ms, n = 13, p < 0.05). The additional increase in LV-dp/dt max in response to augmenting concentrations of NE exceeded the increase in LV-dp/ dt max that was exerted by NE (0.1 and 1 Amol/L) in the absence of ET-1 (Fig. 4A) . In contrast, preperfusion of ET-1 did not potentiate the Iso-induced increase in LV-dp/dt max at any Iso concentration (Fig. 4B) .
ET A antagonism attenuates NET downregulation in experimental heart failure
To investigate whether an activated endogenous endothelin system downregulates NET in experimental CHF, TAC rats were treated with the specific ET A antagonist darusentan. In accordance with our previous findings [26] , 4 weeks after surgery TAC rats developed increased heart weight/body weight and lung wet weight/body weight ratios as well as an impaired cardiac [ 3 H]-NE-uptake and reduced NET binding sites ( Table 1) . As a neurohormonal marker for the severity of CHF, plasma proANP was more than tripled in TAC rats as compared to sham rats (Table 1) . Elevated LV-ET-1 levels confirmed an activation of the local cardiac endothelin system (Table 1) . Darusentan did not lower the organ weights or the plasma proANP level in TAC rats. We observed rather a slight but not significant increase in heart and lung wet weight/body weight ratios and a significant 36% elevation of plasma proANP as compared to nontreated TAC rats (Table 1) . This is most likely due to a darusentan-induced lowering of preload below a level that is required to overcome the hemodynamic burden of aortic stenosis. In contrast, darusentan significantly attenuated both the impairment of [ 3 H]-NE-uptake and the reduction of NET binding sites (Table 1) .
Discussion
In this study we report that ET-1 inhibits NET function through ET A activation. We demonstrate that potentiation of the NE-induced increase in LV contractility by ET-1 is NETdependent. Moreover, evidence is provided that downregulation of NET in failing hearts is mediated by an activated endogenous endothelin system.
Potentiation of NE-induced increase in LV contractility-postsynaptic versus presynaptic
It has been shown that pretreatment of mesenteric [8, 20, 31] , mammary [3] and pulmonary arteries [19] or the aorta [4] with threshold concentrations of ET-1 (0.1 -0.3 nmol/L) potentiates NE-induced contractile responses. Early Isovolumically contracting isolated perfused rat hearts. The increase in LV-dp/dt max reflects the additional increase compared to the LV-dp/dt max after 30 min preperfusion with tyrode alone or ET-1. (A) Increase in LV-dp/ dt max due to increasing concentrations of NE (0.001 -1 mmol/L) after 30 min preperfusion with either tyrode alone (open bars; n = 5) or ET-1 (black bars; 100 pmol/L; n = 6). (B) Increase in LV-dp/dt max due to increasing concentrations of isoprenaline (Iso; 0.001 -1 mmol/L) after 30 min preperfusion with either tyrode alone (open bars; n = 4) or ET-1 (black bars; 100 pmol/L; n = 7).
studies reported that ET-1 attenuates NE release and contractile responses due to sympathetic nerve stimulation, whereas it enhances contractile responses due to NE [8, 19, 20] . These findings imply that ET-1 mediates inhibitory effects on presynaptic neurotransmission and activating effects on postsynaptic noradrenergic signaling. Many studies confirmed the finding that ET-1 inhibits NE release through activation of ET B [13 -15,32 -34] . However, the nature of the modulatory role of ET-1 on sympathetic neurotransmission seems to be more complex, since other studies have shown enhancing or neutral effects of ET-1 on NE release or nerve-stimulated pressure responses [14 -19] .
Most of the studies, that investigated effects of ET-1 on NEor stimulation-induced responses, used preparations of isolated arteries or the adrenal gland. To our knowledge no data are available about presynaptic effects of ET-1 on cardiac sympathetic neurotransmission and on its potentiation of NE-induced increase in cardiac contractility. Here we show in a Langendorff preparation that besides an ET Bmediated inhibitory effect on cardiac exocytotic NE release, ET-1 also reduces NE re-uptake via ET A , resulting in an enhanced NE net release within the heart. The observation, that ET-1 potentiates only the NE-but not the Iso-(that is not taken up by the NET [24] ) induced increase in LV contractility, strongly suggests that this identified presynaptic role of ET-1 might enhance NE-induced effects on cardiac function.
Exocytotic NE release, NE re-uptake and NE net release-ET A versus ET B
Opposite results regarding NE release after pretreatment with ET-1 have been described [13 -19] . We observed an increase in stimulated NE overflow after preperfusion with ET-1. But in the presence of the specific NET inhibitor DMI we found a marked reduction via ET B . This confirms that the increase in the absence of DMI is mediated by ET-1-induced reduction of NE re-uptake via ET A . But it also implies that in cardiac sympathetic neurotransmission the inhibitory effect of ET-1 on NE re-uptake exceeds the inhibition of NE release with the functional consequence that ET-1 increases NE net release. To our knowledge, in most of the studies, that evaluated effects of ET-1 on NE release, no NET inhibitor was added to the perfusion system. Therefore, those studies did not distinguish between exocytotic NE release and NE re-uptake. Consequently, dependent on the ET A /ET B balance within the investigated tissue, the measured NE net release after pretreatment with ET-1 was inhibited, enhanced or neutralized. In accordance with our results, one study, that investigated NE release in the presence of DMI, reported a marked inhibition of NE release via ET B [32] . Taken together, we conclude that the balance between ET B -mediated inhibition of exocytotic NE release and ET A -mediated inhibition of NE re-uptake regulates NE net release and subsequently activation of postsynaptic adrenergic signaling.
Role of endogenous ET-1 for NET downregulation in CHF
As shown previously, impairment of NE re-uptake in an experimental model of CHF is mediated by posttranscriptional downregulation of NET per nerve ending, but the underlying presynaptic mechanism remained unclear [26] . Interestingly, it has been shown that PKC activation in cultured cells leads to translocation of NET or similar neurotransmitter transporters (dopamine transporter) from the plasma membrane to the cytosol and subsequently to its degradation [29, 35] . Preliminary data (not shown) suggest that ET-1 inhibits NE re-uptake also through a PKCdependent pathway. Because the experiments shown in this study were done in a Langendorff preparation, the observed NET modulation is also caused by a posttranscriptional mechanism. As shown before [26] , rats with TAC are known to develop an impaired NE re-uptake without a reduction of sympathetic nerve density [26] . In this study, we show that in the same CHF model ET A antagonism improved both NET function and binding sites. Since TAC rats did not show any improvement in other CHF markers, the observed increase in NET function and density is rather due to a direct effect on sympathetic nerve endings and not secondary due to an improved cardiac function. Recent studies provided evidence that endogenous ET-1 contributes to elevated NE plasma levels and sympathetic nerve activity in experimental CHF [11, 12] . The present study suggests that NET downregulation and subsequent an increased NE net release in failing hearts is mediated by activation of presynaptic ET A on cardiac sympathetic nerve endings. We can rule out that ET-1 acts through modulation of the central sympathetic tone on NET function, because the used Langendorff model was independent of central control. There is still a possibility that ET-1 activates the ET A on cardiomyocytes or other cardiac cell types, which in turn induces secretion of unknown factors that mediate the described effects. Recently, it has been shown that cardiomyocyte-specific ET A -knockout mice exhibit normal heart growth and normal hypertrophic and contractile responses due to angiotensin II or Iso [36] . However, we cannot completely rule out that ET A of other cardiac cell types (e.g. fibroblasts or endothelial cells) affects NET on sympathetic cells indirectly. Nevertheless, we anticipate that the presynaptic ET A on cardiac sympathetic cells regulates NET function and consequently cardiac remodeling in CHF.
Clinical implications
Both elevated plasma levels of ET-1 and an impaired NE re-uptake are predictors of mortality in patients with CHF [37] . The results of the present study suggest that a selective ET A blockade attenuates sympathetic overstimulation of failing hearts via an enhanced NE re-uptake and a preserved ET B -mediated inhibition of exocytotic NE release. Likewise, it has been shown that the ET B agonist StxS6c protects against ischemia-induced arrhythmias and decreases myocardial infarct size [38, 39] . Although experimental studies reported beneficial effects of endothelin blockade on survival in CHF [40] , long term treatment with the nonselective ET A and ET B inhibitor bosentan failed to reduce morbidity or mortality in CHF patients [41] . Moreover, treatment of CHF patients for 6 months with the specific ET A antagonist darusentan did not improve cardiac remodeling (EARTH Trial) [42] . The neutral result of the EARTH Trial could be explained by the background treatment. Whereas ACE inhibitors and AT 1 antagonists are known to decrease local cardiac ET-1 production [43] , beta-blockers already attenuate sympathetic overstimulation of failing hearts. Nevertheless, ET A antagonists might be promising drugs in the management of CHF patients who are intolerant to ACE inhibitors and/or beta-blockers. Moreover, compared to beta-blockers, ET A antagonists would have the advantage that they potentially prevent an impairment of NE re-uptake and consequently depletion of cardiac NE stores in the sympathetic nerve ending [26] , therefore ultimately preserving noradrenergic responses to stress and exercise [44] .
Summary
This study demonstrates that ET-1 impairs cardiac NET function, resulting in a potentiated response to NE-induced LV contractility. Evidence is provided that downregulation of NET in failing hearts is at least in part mediated by an activated endogenous endothelin system.
